BioSpace News Archive

IntuitiveX (IX), a Seattle-based life sciences consultancy and incubator, collaborates with NavLab to create more IP in the surgical robotics space.

Endo International plc announced that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference in Boca Raton, Florida on Tuesday, December 3, 2019 at 8:50 a.m. ET..

Hutchison China MediTech Limited will share analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress on November 22 to 24, 2019 in Singapore.

The integration of Encoda’s claims management and analytics tools with Nextech Practice Management software brings smarter revenue cycle management strategy to specialty practices

ProHEALTH Care, the largest, independent, physician-run healthcare organization in the nation, expands its pediatric department with the addition of two new subspecialty physicians, Louis Rigos, DO, MPH, pediatric cardiologist and Ari Goldsmith, MD, FAAP, pediatric otolaryngologist.

A well-known market intelligence company, Infiniti Research, has announced the completion of its latest article on Types of Marketing Strategies for Pharmaceutical Companies to Boost Profits.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium.

Senzer’s pharmaceutical cannabinoid device has won another major design award, with the German Design Council commending the unique inhaler for having ‘a clear modern design that perfectly combines ergonomics and functionality’.

Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatment of major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD.